Editorial: El País

• The advances presented at the International AIDS Society congress are extraordinary.
• A drug called lenacapavir has shown 100% effectiveness in preventing HIV transmission in women.
• The problem is the high cost of lenacapavir, which makes it inaccessible to developing countries.
• Gilead Sciences, the company that developed the drug, is being pressured to allow the sale of generics in low and middle income countries.
• The production cost of lenacapavir could be significantly reduced if mass produced.

Conclusion: Lenacapavir represents an extraordinary advance in the fight against HIV, but its high cost and need to make it accessible in low-income countries present significant challenges.

---